ELTX Company Profile and Key Details

Elicio Therapeutics, Inc. (NASDAQ:ELTX) closed at $14.30 USD, gaining $0.10 (0.70%) from the previous close of $14.20. The stock is currently mid-range between its 52-week high and low $7.37 and $16.00. With a market capitalization of about $272.93 million, Elicio Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.14). Key stats such as the average daily volume over the past year has been around 128.21 thousand shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Elicio Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert T. Connelly, the company employs approximately 32 people and listed since February 05, 2021. Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases.

ELTX has shown mixed momentum, gaining 2.71% over the past week and -14.97% over the past quarter, though year-to-date performance is down -0.13%. Short-term trend indicators are mixed aligned (SMA20 33.3%, SMA50 40.47%, SMA200 31.09%). The stock’s 14-day RSI is 77.6 (overbought), while the ATR of 0.75 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.97% below its high and over 155.22% above its low. Average 10-day trading volume of 160.03 thousand shares is slightly above the 3-month average of 135.18 thousand, indicating heightened recent market interest.

Elicio Therapeutics, Inc. trades at a P/E ratio of -6.47, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -180.91 indicating negative book value, which may reflect financial stress. The P/FCF stands at -7.08, also below market averages.

Elicio Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.26. This means the shares are trading above this model’s fair value.

Elicio Therapeutics, Inc. generated EPS of -$3.40 over the past year. Five-year average earnings growth is 20.96%. Wall Street analysts project EPS growth of 30.94% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $13.00. The high target offers 88.81% upside. The low target suggests -9.09% downside. The mean target is $18.50. This offers 29.37% upside. Elicio Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 32.65%. The prior quarter beat by 4.26%. Over the last six quarters, Apple has recorded several small beats. These include 8.51% in March 31, 2025.

Elicio Therapeutics, Inc. has 16.34 million shares outstanding. The public float is 10.64 million shares, elevated short interest at 4.04% of float. This equals 416.96 thousand shares. The short ratio is 11.15 days. Institutional investors hold 16.91% of the float. Insiders own 42.96%.

Elicio Therapeutics, Inc. (NASDAQ:ELTX) shares are flat -0.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Elicio Therapeutics, Inc. trading at a premium to the broader market with a P/E of -6.47. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.38, suggesting 14.55% upside. Our AI forecast model points to short-term strength (14.27% over two weeks), a medium-term rise (16.71% over three months), and a longer-term gain (126.29% over one year), with expected trading ranges indicating moderate volatility.